These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11745931)

  • 1. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment.
    Sagnelli E; Coppola N; Scolastico C; Mogavero AR; Stanzione M; Filippini P; Felaco FM; Piccinino F
    J Med Virol; 2001 Dec; 65(4):681-7. PubMed ID: 11745931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    Arch Virol; 1997; 142(3):535-44. PubMed ID: 9349299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of previous HBV infection on the course of chronic hepatitis C.
    De Maria N; Colantoni A; Friedlander L; Leandro G; Idilman R; Harig J; Van Thiel DH
    Am J Gastroenterol; 2000 Dec; 95(12):3529-36. PubMed ID: 11151889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease.
    Sagnelli E; Coppola N; Scolastico C; Mogavero AR; Filippini P; Piccinino F
    J Med Virol; 2001 Jul; 64(3):350-5. PubMed ID: 11424125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
    Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
    J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C.
    Myers RP; Thibault V; Poynard T
    J Viral Hepat; 2003 Mar; 10(2):103-10. PubMed ID: 12614466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
    Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
    Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
    Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
    Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A
    J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
    Toyoda H; Kumada T; Tada T; Murakami Y
    J Clin Gastroenterol; 2014 Jan; 48(1):73-9. PubMed ID: 23842217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study.
    Colombatto P; Baldi M; Oliveri F; Randone A; Bonino F; Brunetto MR
    Dig Liver Dis; 2000 Apr; 32(3):211-6. PubMed ID: 10975771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.